Hamsa Biopharma, which will take the drug — Christened TGR63 — to trials through its parent company in the US, IGC Pharma, hopes it can eventually be made available in the market.
The FIRST natural cannabis-based patent-protected compound that relies on low doses of THC, a psychoactive cannabinoid, and another compound as active agents for the treatment of Alzheimer’s disease.
Researchers in India say they have discovered a promising drug target that may slow or even halt the progression of Alzheimer’s.
The original patent application was initiated by the University of South Florida (“USF”) and filed on July 30, 2015. On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimer’s disease.
